CatSci adds cGMP analytical development services

Scientist using a laptop

UK-based CatSci have expanded their offering to now include cGMP analytical capabilities for both small molecule and oligonucleotides.

The new cGMP analytical capability will be led by Dr Sam Whitmarsh and Duncan Thompson, CatSci’s Director of Analytical Science and Digital Transformation, and Head of Dagenham site respectively.

Dr Nigel Richardson, CatSci’s Director of New Modalities, will lead the analytical development of oligonucleotides. QP Consultant Kate Smith will oversee all quality aspects.

The company’s analytical team will provide ICH Q14 aligned method development and validation, ICH Q3D elemental analysis, batch release, ICH stability testing, extractables and leachables, and oligonucleotides analytical development.

Dr Whitmarsh said: “After much hard work by our amazing team and a great partnership with Shimadzu, I am excited to launch this new chapter for analytical science at CatSci. The opening of our state-of-the-art GMP analytical facilities is not just a new space, it is a commitment to tackling key analytical challenges facing our customers, from method development and validation to oligonucleotides and trace analysis.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free